Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, ...
Stocktwits on MSN
ATOS stock jumps 8% today – an FDA designation draws investor cheer for Atossa Therapeutics
The RPD designation is given to therapies targeting serious or life-threatening conditions that primarily affect children. ・(Z)-endoxifen already has an RPD designation for the treatment of Duchenne ...
Atossa Therapeutics (NASDAQ:ATOS) added ~17% to rise sharply for the second straight session on Wednesday after announcing that enrollment in a mid-stage trial for its experimental breast cancer ...
The MarketWatch News Department was not involved in the creation of this content. Recognized for Visionary Leadership and Advancing Innovative Therapies in Oncology and Healthcare Technology SEATTLE, ...
Atossa Therapeutics, Inc. expressed disappointment over the Patent Trial and Appeal Board's ruling deeming all challenged claims of U.S. Patent No. 11,572,334 unpatentable. While Atossa will not ...
The average one-year price target for Atossa Therapeutics (NasdaqCM:ATOS) has been revised to $23.46 / share. This is a ...
What To Know: The FDA granted one of the biopharmaceutical company’s potential treatments, (Z)-Endoxifen, a rare pediatric disease designation for the treatment of Duchenne Muscular Dystrophy. The ...
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Atossa Genetics Inc. (ATOS) one of those stocks right now? Let ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results